1623 Capital’s Apellis Pharmaceuticals APLS Stock Holding History

1623 Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,655	Closed	-$71K	–	73
2021 Q1	$71K	Buy	+1,655	New	+$78.3K	0.03%	77

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

1623 Capital's APLS Position: Q2 2021 in Review

1623 Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2021, closing a stake of 1,655 shares — an estimated $71K sold.

1623 Capital first reported a position in APLS in Q1 2021 and held it in 1 quarter. The position peaked at $71K in Q1 2021. 204 funds tracked by Wall St. Rank hold APLS as of Q2 2021.

1623 Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
1623 Capital sold 1,655 Apellis Pharmaceuticals shares in Q2 2021, an estimated $71K.
1623 Capital first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 1 quarter.
1623 Capital's Apellis Pharmaceuticals position peaked at $71K in Q1 2021.
204 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2021.

Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.